Drug Profile
Muscular dystrophy gene therapy - Transgene/Roche Madison
Alternative Names: Myodys; TG 5001Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Association Francaise contre les Myopathies; Transgene
- Developer Roche Madison; Transgene
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Muscular dystrophies
- Discontinued Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Muscular-dystrophies in France (Parenteral)
- 24 Oct 2011 Roche Madison has been acquired by Arrowhead Research Corporation
- 15 Jun 2009 Clinical development is ongoing in France